Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand

Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand

© 2019 ISPOR–The professional society for health economics and outcomes research Objective: To assess the cost-effectiveness of first-line chemotherapy regimens for non-small cell lung cancer patients in Thailand. Methods: A Markov model comprising 3 health states (progression-free survival, progres...

Full description

Saved in:

Bibliographic Details
Main Authors:	Unchalee Permsuwan, Sumitra Thongprasert, Buntitabhon Sirichanchuen
Format:	Journal
Published:	2020
Subjects:	Economics, Econometrics and Finance Medicine Pharmacology, Toxicology and Pharmaceutics
Online Access:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85073458329&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/68362
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	Chiang Mai University

Similar Items

An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia
by: John Wen Cheng Chang, et al.
Published: (2018)

An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia
by: Chang J.W.-C., et al.
Published: (2014)

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
by: Sumitra Thongprasert, et al.
Published: (2018)

Epidermal growth factor receptor mutation testing in Thailand: A cost-utility analysis
by: Unchalee Permsuwan, et al.
Published: (2018)

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
by: Thongprasert S., et al.
Published: (2014)

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
by: Thongprasert S., et al.
Published: (2014)

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective
by: Tan, P.-T, et al.
Published: (2020)

Preliminary study of efficacy of intravenous cisplatin plus oral etoposide in small cell lung cancer
by: Chewaskulyong B., et al.
Published: (2014)

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
by: James Chih Hsin Yang, et al.
Published: (2018)

Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
by: Sumitra Thongprasert, et al.
Published: (2018)

Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
by: Sumitra Thongprasert, et al.
Published: (2018)

Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
by: Thongprasert,S., et al.
Published: (2015)

Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
by: Thongprasert S., et al.
Published: (2014)

Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer
by: Thongprasert S., et al.
Published: (2014)

First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results from a Randomized Phase III Trial
by: Mark Boye, et al.
Published: (2018)

Efficacy and safety of first-line necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in East Asian patients with stage IV squamous non-small cell lung cancer: A subgroup analysis of the phase 3, open-label, randomized SQUIRE study
by: Keunchil Park, et al.
Published: (2018)

Efficacy and safety of first-line necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in East Asian patients with stage IV squamous non-small cell lung cancer: A subgroup analysis of the phase 3, open-label, randomized SQUIRE study
by: Keunchil Park, et al.
Published: (2018)

Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials
by: Pajaree Sriuttha, et al.
Published: (2018)

Epidermal growth factor receptor mutation testing in Thailand: A cost-utility analysis
by: Unchalee Permsuwan, et al.
Published: (2018)

Cost-utility analysis of vasoconstrictors plus albumin in the treatment of thai patients with type 1 hepatorenal syndrome
by: Sermsiri Sangroongruangsri, et al.
Published: (2022)

Combination of gemcitabine and cisplatin in advanced non-small cell lung cancer
by: Thongprasert S., et al.
Published: (2014)

Cost–Utility Analysis of Transcatheter Aortic Valve Implantation versus Surgery in High-Risk Severe Aortic Stenosis Patients in Thailand
by: Permsuwan U.
Published: (2023)

Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china
by: You, R., et al.
Published: (2021)

Cost-effectiveness analysis of the adjunctive therapy of ivabradine for the treatment of heart failure with reduced ejection fraction
by: Rungroj Krittayaphong, et al.
Published: (2020)

Ifosfamide, epirubicin and cisplatin (IEP): another active combination for small cell lung cancer (SCLC)
by: Thongprasert S., et al.
Published: (2014)

Treatment costs for patients with chronic kidney disease who received multidisciplinary care in a district hospital in thailand
by: Suwaporn Songsermlosakul, et al.
Published: (2020)

Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer
by: Chaiyut Charoentum, et al.
Published: (2018)

Efficacy and tolerability of tropisetron in the prevention of cisplatin-induced nausea and vomiting in advanced non-small cell lung cancer
by: Thongprasert S.
Published: (2014)

Cost–Utility Analysis of Transcatheter Aortic Valve Implantation versus Surgery in High-Risk Severe Aortic Stenosis Patients in Thailand
by: Unchalee Permsuwan, et al.
Published: (2022)

Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand
by: Chaicharn Deerochanawong, et al.
Published: (2019)

Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand
by: Unchalee Permsuwan, et al.
Published: (2018)

Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma
by: Thongprasert S., et al.
Published: (2014)

Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma
by: S. Thongprasert, et al.
Published: (2018)

Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand
by: Unchalee Permsuwan, et al.
Published: (2018)

Cost-utility analysis of dapagliflozin compared to sulfonylureas for type 2 diabetes as second-line treatment in indian healthcare payer’s perspective
by: Bhavani Shankara Bagepally, et al.
Published: (2022)

Paclitaxel and carboplatin plus megestrol acetate in the treatment of advanced non-small cell lung cancer
by: Thongprasert S., et al.
Published: (2014)

Phase II study of three days' fractionated dosage of ifosfamide, epirubicin and cisplatin in small cell lung cancer
by: Thongprasert S., et al.
Published: (2014)

Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
by: Thongprasert S., et al.
Published: (2017)

Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer
by: Charoentum C., et al.
Published: (2014)

Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer
by: Thongprasert S., et al.
Published: (2014)